Table 1.
Characteristics of patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer (MBC) treated with nab-paclitaxel and S-1 combination therapy (n = 15)
| Characteristic | No. of patients (%) |
|---|---|
| Age, years | |
| Median (range) | 63.0 (41–67) |
| ECOG PS | |
| 0 | 9 (60.0) |
| 1 | 6 (40.0) |
| Hormonal status | |
| ER-positive and/or PgR-positive | 11 (73.3) |
| ER-negative and PgR-negative | 4 (26.7) |
| Metastatic site | |
| Lung | 6 (40.0) |
| Bone | 9 (60.0) |
| Liver | 4 (26.7) |
| Distant lymph nodes | 6 (40.0) |
| Other | 3 (20.0) |
| Prior chemotherapy for MBC | |
| 0 | 9 (60.0) |
| 1 | 6 (40.0) |
ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PgR, progesterone receptor; PS, performance status.